12 / 20
Page 26
Notes:
allied
academies
September 20-21, 2017 | Philadelphia, USA
Global summit on
TUBERCULOSIS AND LUNG DISEASE
Int J Respir Med 2017 Volume 2 Issue 2
S
urgery was one of the main treatment options for
tuberculosis before the introduction of effective anti-
tuberculosis medicines. Early surgical therapies consisted
of a variety of collapse therapies including thoracoplasty,
ball plombage, artificial pneumothorax and phrenicotomy
and the first report of pulmonary resection was in 1891.
Although surgery played a prominent role in tuberculosis
management during the early twentieth century, it was
largely abandoned with the introduction of modern anti-
tuberculosis chemotherapy and chemotherapy has been the
main treatment method for tuberculosis until the present
day. However, the global emergence of drug-resistant TB
including multidrug resistant (MDR) and extensively drug-
resistant (XDR) disease has led to the re-examination of
surgery as an adjunctive treatment for highly drug-resistant
TB and there are few reports of long-term prognosis. We
have carried out a retrospective analysis on 25 pulmonary
tuberculosis sequelae cases due to surgical procedures. The
analysis was based on the medical records of tuberculosis
sequelae cases who visited Ibarakihigashi National Hospital
from 2012 to 2016. They include 10 thoracoplasty cases,
6 pneumonectomy cases, 6 upper lobe resection cases, 2
artificial pneumothorax cases and 1 phrenicotomy case.
Although 16 of 18 cases with spirometry data available had
restrictive ventilatory defect after a median time of 60 years
from surgical procedures, 25 cases survived for a media
time of 56 years from surgery, though 7 cases needed long-
term oxygen therapy and 5 cases did non-invasive positive
pressure ventilation. Most cases of pulmonary tuberculosis
sequelae due to surgical procedures survived for a long time
after surgery. This study suggests that surgical procedures
may be an important element of successful therapy for non-
tuberculous mycobacteria, MDR-TB or XDR-TB with limited
therapeutic options.
Speaker Biography
Mizu Nonaka has completed his MD from University of Tsukuba, Japan. He belongs to
Department of Respiratory Medicine, Ibarakihigashi National Hospital.
e:
mizu.nonaka85@gmail.com25 cases with pulmonary tuberculosis sequelae due to surgical procedures; Experience in Japan
Mizu Nonaka, Hitomi Goto, Rie Shigemasa, Yuika Sasatani, Naoki Arai, Kai Yazaki, Hiroaki Ishikawa, Kentaro Hyodo, Kenji Nemoto, Yukiko Miura, Takio
Takaku, Shuji Oishi, Kenji Hayashihara
and
Takefumi Saito
Ibaraki Higashi National Hospital, Japan